Fosfomycin: Difference between revisions
No edit summary |
No edit summary |
||
(14 intermediate revisions by 6 users not shown) | |||
Line 1: | Line 1: | ||
==General== | ==General== | ||
*Type: | *Type: [[Antibiotic]] | ||
*Dosage Forms: | *Dosage Forms: oral | ||
*Common Trade Names: | *Common Trade Names: Monurol | ||
==Adult Dosing== | ==Adult Dosing== | ||
*Uncomplicated UTI: 3g PO x 1 | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*>12 y/o: 3 g PO x 1 | |||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: B | ||
*Lactation: | *Lactation Risk: Infant risk cannot be ruled out | ||
*Renal Dosing | *Renal Dosing: Half life increased in renal impairment, no specific adjustment | ||
*Hepatic dosing: no adjustment | |||
*Hepatic | |||
==Contraindications== | ==Contraindications== | ||
*Allergy to class/drug | *Allergy to class/drug | ||
*Caution if hepatic impairment | |||
*Caution if recent antibiotic-associated colitis | |||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*Angioedema | |||
*Aplastic Anemia | |||
*Asthma Exacerbation | |||
*Hepatic Necrosis | |||
*Toxic Megacolon | |||
*C. difficile diarrhea | |||
===Common=== | ===Common=== | ||
*[[Diarrhea]] | |||
*Vaginitis | |||
*Rhinitis | |||
*nausea | |||
*headache | |||
*dizziness | |||
*back pain | |||
*abdominal pain | |||
*dysmenorrhea | |||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: 5.7 hours | ||
*Metabolism: | *Metabolism: | ||
*Excretion: | *Excretion: Urine 38%, Feces 18% | ||
*Mechanism of Action: | *Mechanism of Action: Bactericidal, inhibits cell wall synthesis | ||
==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>== | ==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>== | ||
Line 155: | Line 170: | ||
==See Also== | ==See Also== | ||
== | ==References== | ||
<references/> | |||
[[Category:Pharmacology]] | |||
[[Category: |
Revision as of 22:24, 21 October 2017
General
- Type: Antibiotic
- Dosage Forms: oral
- Common Trade Names: Monurol
Adult Dosing
- Uncomplicated UTI: 3g PO x 1
Pediatric Dosing
- >12 y/o: 3 g PO x 1
Special Populations
- Pregnancy Rating: B
- Lactation Risk: Infant risk cannot be ruled out
- Renal Dosing: Half life increased in renal impairment, no specific adjustment
- Hepatic dosing: no adjustment
Contraindications
- Allergy to class/drug
- Caution if hepatic impairment
- Caution if recent antibiotic-associated colitis
Adverse Reactions
Serious
- Angioedema
- Aplastic Anemia
- Asthma Exacerbation
- Hepatic Necrosis
- Toxic Megacolon
- C. difficile diarrhea
Common
- Diarrhea
- Vaginitis
- Rhinitis
- nausea
- headache
- dizziness
- back pain
- abdominal pain
- dysmenorrhea
Pharmacology
- Half-life: 5.7 hours
- Metabolism:
- Excretion: Urine 38%, Feces 18%
- Mechanism of Action: Bactericidal, inhibits cell wall synthesis
Antibiotic Sensitivities[1]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
See Also
References
- ↑ Sanford Guide to Antimicrobial Therapy 2014